ARVN
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110 and ARV-471. The company was founded in February 2013 and is headquartered in New Haven, CT.
Arvinas, Inc. (ARVN) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B); its weakest is Growth (F).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | B (3.2) | F (0.2) | B- (3.1) | C- (2.0) | C+ (2.6) | C (2.2) |
| 2026-11-10 | B (3.3) | F (0.2) | B- (3.1) | C- (2.1) | C+ (2.6) | C (2.3) |
| 2026-11-03 | B- (3.1) | F (0.3) | B- (3.1) | C- (2.0) | F (0.0) | D+ (1.7) |
| 2026-10-27 | B- (3.1) | F (0.3) | B- (3.1) | C- (2.1) | F (0.0) | D+ (1.7) |
| 2026-10-20 | B- (3.1) | F (0.3) | B- (3.1) | C- (2.1) | F (0.0) | D+ (1.7) |